EXPERIENCE WITH POPULIN WITH DIHYDROQUERCETIN IN NOVEL CORONAVIRUS INFECTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the efficacy of BAA populin with dihydroquercetin in patients with COVID-19. Subjects and methods. Sixty patients diagnosed with COVID-19 in the early stage of convalescence were followed up. Thirty persons of them took populin with dihydroquercetin (a study group), the other 30 patients received basic therapy (a comparison group). The mean age was 52.08±11.9 years. There was a female preponderance in both groups. Results. The incorporation of populin with dihydroquercetin into the combination therapy of patients with COVID-19 contributed to a faster normalization of clinical and laboratory parameters and to a significantly rapid rise in SARS-CoV-2 IgG antibody titers. The drug contributed to a more rapid normalization of the inflammatory process in the lungs, as evidenced by computed tomography. Conclusion. It is advisable to incorporate BA A populin with dihydroquercetin into the combination treatment of patients with COVID-19.

Full Text

Restricted Access

About the authors

Vera V. Makashova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: veramakashova@yandex.ru
MD, Leading Researcher, Clinical Department of Infectious Diseases Moscow, Russia

Zhanna B. Ponezheva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: doktorim@mail.ru
MD, Head, Clinical Department of Infectious Diseases Moscow, Russia

Khadizhat G. Omarova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: omarova71@inbox.ru
Cand. Med. Sci., Head, Clinical Research Department Moscow, Russia

Valentina N. Burkova

OOO "BIOLIT"

Email: info@biolit.info
ChD, Academician of the Russian Academy of Natural Sciences, Director for Science and Innovations Tomsk, Russia

Valery P. Sergun

OOO "BIOLIT"

Email: info@biolit.info
Cand. Chem. Sci., Director Tomsk, Russia

Aleksandr V. Gorelov

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: crie@pcr.ru
MD, Academician of the Russian Academy of Sciences; Deputy Director for Science; Head, Department of Infectious Diseases and Epidemiology Moscow, Russia

References

  1. Ханин А.Л., Буркова В.Н., Стрелис А.К., Викторова И.Б. и др. Методические рекомендации по клиническому исследованию лечебного эффекта препарата Популин при туберкулезе легких. Томск, 2006. 16 с
  2. Ханин А.Л., Викторова И.Б. Популин в комплексном лечении больных туберкулезом легких: учебно-методическое пособие для врачей. Новокузнецк, 2010. 44 с
  3. Буркова В.Н., Иванов А.А., Сергун В.П. Осина в доказательной медицине XXI века. Томск, 2020: 94-107

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media